AgomAb Therapeutics N.V. American Depositary Shares
AGMBHealthcare|Biotechnology|BE
$7.63
+0.67 (+9.54%)
DCF Value
$1.89
Tangible Book / Share
$4.86
Cash / Share
$5.17
Financials
Financial Snapshot
Market Cap
$376.0M
Enterprise Value
$116.6M
Revenue (TTM)
—
Net Income (TTM)
—
Cash & Investments
—
Net Cash
—
Free Cash Flow (TTM)
—
Operating CF (TTM)
—
Debt/Equity
0.00
R&D Spending
R&D (2025)
$48.9M
R&D Intensity
—
R&D Growth vs Prior
+24.3%
| Metric | Trend | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $19.4M | $26.3M | $39.3M | $48.9M | |
| SG&A | $4.5M | $6.0M | $9.8M | $12.6M |
Income Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $19.4M | $26.3M | $39.3M | $48.9M | |
| SG&A | $4.5M | $6.0M | $9.8M | $12.6M | |
| Operating Income | -$22.6M | -$31.2M | -$48.0M | -$59.3M | |
| Interest Expense | $45.0K | $31.0K | $67.0K | $60.0K | |
| Pretax Income | -$10.8M | -$12.0M | -$46.3M | -$62.5M | |
| Net Income | -$8.1M | -$11.4M | -$46.3M | -$62.5M | |
| EPS (Diluted) | -0.22 | -0.31 | -1.26 | -1.28 | |
| EBITDA | -$10.7M | -$11.9M | -$45.9M | -$62.3M | |
| Shares Out. (M) | 36.24 | 36.24 | 36.24 | 48.74 |
Balance Sheet
| Metric | Trend | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | — | — | — | $86.4M | |
| Short-Term Investments | — | — | — | $30.1M | |
| Total Current Assets | — | — | — | $121.2M | |
| Total Assets | — | — | — | $153.7M | |
| Total Current Liabilities | — | — | — | $18.6M | |
| Long-Term Debt | — | — | — | $0.00 | |
| Total Liabilities | — | — | — | $22.8M | |
| Stockholders' Equity | — | — | — | $130.9M | |
| Retained Earnings | — | — | — | -$181.7M |
Cash Flow Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | — | — | — | -$51.7M | |
| Capital Expenditure | — | — | — | -$4.0K | |
| Free Cash Flow | — | — | — | -$51.7M | |
| Investing Cash Flow | — | — | — | -$33.0M | |
| Financing Cash Flow | — | — | — | -$338.0K | |
| Issuance of Stock | — | — | — | $0.00 | |
| Repurchase of Stock | — | — | — | $0.00 | |
| Net Debt Issuance | — | — | — | -$338.0K | |
| Stock Based Comp. | — | — | — | $5.4M | |
| Net Change in Cash | — | — | — | -$85.0M |
Dilution Tracker
Shares outstanding grew 34.5% over 5 years — significant dilution
Shares Outstanding
49M
5-Year Share Growth
+34.5%
Stock Issuance (2025)
$0.00
| Metric | Trend | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Shares Out. (M) | 36.24 | 36.24 | 36.24 | 48.74 | |
| Change vs Prior % | — | 0.0% | 0.0% | 34.5% | |
| Stock Issuance | — | — | — | $0.00 | |
| Stock Repurchase | — | — | — | $0.00 | |
| Stock Based Comp. | — | — | — | $5.4M |
Margins & Profitability
| Metric | Trend | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| ROE % | 0.0% | 0.0% | 0.0% | -47.8% | |
| ROA % | 0.0% | 0.0% | 0.0% | -40.7% | |
| ROIC % | 0.0% | 0.0% | 0.0% | -43.8% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -37.8% | -54.0% | -23.4% | |
| Net Income | 0.0% | -39.9% | -306.2% | -35.2% | |
| EPS (Diluted) | 0.0% | -40.9% | -306.5% | -1.6% | |
| Operating Cash Flow | 0.0% | 0.0% | 0.0% | 0.0% | |
| Free Cash Flow | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D Expense | 0.0% | 35.5% | 49.4% | 24.3% | |
| SG&A Expense | 0.0% | 33.6% | 63.8% | 28.0% | |
| Total Assets | 0.0% | 0.0% | 0.0% | 0.0% | |
| Book Value / Share | 0.0% | 0.0% | 0.0% | 0.0% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 34.5% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B1.26
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.89
Tangible Book / Share
$4.86
Net Current Assets / Share
$4.73
Graham Net-Net
$4.65
Cash / Share
$5.17
| Metric | Trend | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| P/E Ratio | -62.19 | -42.75 | -11.23 | -9.74 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 0.00 | 0.00 | 0.00 | 4.64 | |
| EV/EBITDA | 0.00 | 0.00 | 0.00 | -8.39 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $443.3K | $531.9K | $1.0M |
| Net Income | -$72.9M | -$92.5M | -$112.7M |
| EPS | $-1.75 | $-2.06 | $-2.14 |
| # Analysts (EPS) | 6 | 6 | 6 |